US Patent 9814751 Lisinopril formulations
Patent 9814751 was granted and assigned to Silvergate Pharmaceuticals, Inc. on November, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+265 characters)
Article
Patent abstract
Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
David W. Miles0
Gerold L. Mosher0
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09814751 Lisinopril formulations US Patent 9814751 Lisinopril formulations
Infobox
Patent Number
09814751
Patent Number
9814751
Edits on 15 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09814751 Lisinopril formulations
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09814751
Date of patent
November 14, 2017
Patent application number
15483691
Date Filed
April 10, 2017
Patent primary examiner
Find more entities like US Patent 9814751 Lisinopril formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.